FibroBiologics Announces Preliminary Proof Of Concept For Fibroblast-Based Diabetes Treatment
FibroBiologics Announces Preliminary Proof Of Concept For Fibroblast-Based Diabetes Treatment
FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the progress of a clinical program under development using a fibroblast-based pancreatic beta cell spheroid that secretes insulin in vitro upon glucose stimulation. The development and reproducibility of this work demonstrates that an organoid composed of fibroblasts, beta cells and other components can successfully and durably secrete insulin.
Fibrobiologics, Inc.（纳斯达克股票代码：FBLG）（“Fibrobiologics”）是一家临床阶段的生物技术公司，拥有150多项已颁发和正在申请的专利，专注于使用成纤维细胞和成纤维细胞衍生材料开发慢性病的疗法和潜在的治疗方法。该公司宣布了一项正在开发的使用分泌胰岛素的成纤维细胞胰腺β细胞球体的临床项目的进展 体外 在葡萄糖刺激下。这项研究的发展和可重复性表明，由成纤维细胞、β细胞和其他成分组成的类器官可以成功而持久地分泌胰岛素。
"This early proof of concept is encouraging and may lead to a new and durable potential allogeneic treatment option for people with insulin-dependent diabetes," said Hamid Khoja, Ph.D., Chief Scientific Officer. "We look forward to confirming these early results and in vivo utility. We will then determine whether to designate the program as an early phase pre-clinical project for developing a minimally invasive therapeutic for type 1 diabetes."
首席科学官哈米德·霍贾博士说：“这种早期的概念验证令人鼓舞，可能会为胰岛素依赖型糖尿病患者提供一种新的、持久的潜在异基因治疗选择。”“我们期待确认这些早期结果， 在活体中 效用。然后，我们将决定是否将该项目指定为开发1型糖尿病微创疗法的早期临床前项目。”